Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.

The mALBI 2b patients who were able to receive Atezo+Bev for nine consecutive weeks had no deterioration of hepatic reserve function (Figure 4B ), but those who had imaging PD during treatment showed a trend toward decreased hepatic reserve function.

also in 53,322 other papers